

# United States Patent and Trademark Office

(m)

united States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

PPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/970,532	10/03/2001	Michael J. Taylor	08411-018002	2759
26191 75	590 04/19/2004		EXAMINER	
FISH & RICHARDSON P.C.			O HARA, EILEEN B	
3300 DAIN RAUSCHER PLAZA 60 SOUTH SIXTH STREET			ART UNIT	PAPER NUMBER
**	IS, MN 55402		1646	
			DATE MAILED: 04/19/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

•		Application No.	Annligant(c)				
Office Action Summary		Application No. 09/970,532	Applicant(s) TAYLOR ET AL.				
		Examiner	Art Unit				
	-	Eileen O'Hara	1646				
	The MAILING DATE of this communic			ddress			
Period fo			,				
THE   - External after - If the - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR MAILING DATE OF THIS COMMUNIC nsions of time may be available under the provisions of SIX (6) MONTHS from the mailing date of this communication of the period for reply specified above is less than thirty (30) period for reply is specified above, the maximum stature to reply within the set or extended period for reply with reply received by the Office later than three months after the patent term adjustment. See 37 CFR 1.704(b).	ATION. 37 CFR 1.136(a). In no event, however ication. days, a reply within the statutory minimutory period will apply and will expire SIX II, by statute, cause the application to be	may a reply be timely filed on of thirty (30) days will be considered time (6) MONTHS from the mailing date of this come ABANDONED (35 U.S.C. § 133).	ely. communication.			
Status		,					
1) 又	Responsive to communication(s) filed	on 20 January 2004.					
· —		) This action is non-final.					
, —	<del>_</del>						
,	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Dispositi	on of Claims						
4)  🗆	Claim(s) 29-62 is/are pending in the a	oplication.					
•	4a) Of the above claim(s) is/are withdrawn from consideration.						
	☑ Claim(s) <u>29-40 and 59-62</u> is/are allowed.						
· · · · · · · · · · · · · · · · · · ·	Claim(s) <u>45-58</u> is/are rejected.						
7)🖂	Claim(s) <u>41-44</u> is/are objected to.						
8)□	Claim(s) are subject to restriction	on and/or election requireme	ent.	·			
Applicati	on Papers						
9)□	The specification is objected to by the	Examiner.					
10)⊠ The drawing(s) filed on <u>03 October 2001</u> is/are: a)⊠ accepted or b)□ objected to by the Examiner.							
,	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11)	The oath or declaration is objected to b	y the Examiner. Note the at	tached Office Action or form P	TO-152.			
Priority u	ınder 35 U.S.C. § 119						
12)□	Acknowledgment is made of a claim fo	r foreign priority under 35 U.	S.C. § 119(a)-(d) or (f).				
	☐ All b)☐ Some * c)☐ None of:	, , , , , , , , , , , , , , , , , , ,	3 (-) (-) - (-)				
,	1. Certified copies of the priority do	ocuments have been receive	ed.				
	2. Certified copies of the priority do						
	3. Copies of the certified copies of	the priority documents have	been received in this Nationa	ıl Stage			
	application from the Internationa	al Bureau (PCT Rule 17.2(a)	<b>)</b> .				
* S	See the attached detailed Office action	for a list of the certified copie	es not received.				
Attachmen			, <u>, , , , , , , , , , , , , , , , , , </u>				
	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTC	· —	erview Summary (PTO-413) per No(s)/Mail Date				
3) Inform	nation Disclosure Statement(s) (PTO-1449 or PTr No(s)/Mail Date	TO/SB/08) 5) □ No	tice of Informal Patent Application (PT ner:	O-152)			

Application/Control Number: 09/970,532

Art Unit: 1646

#### **DETAILED ACTION**

1. Claims 29-62 are pending in the instant application. Claims 32 and 33 have been amended, claims 15, 17 and 19 have been canceled and claims 35-62 have been added as requested by Applicant in the Paper filed January 20, 2004.

## Objection to Specification and Sequence Compliance

2. The objection to the specification is withdrawn in view of Applicants' amendment, and the insertion of the sequence identifier in the legend to Fig. 1 is acknowledged.

### Withdrawn Objections and Rejections

3. Any objection or rejection of record which is not expressly repeated in this action has been overcome by Applicant's response and withdrawn.

#### New Objections and Rejections

4. Claims 41-44 are objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. The claims don't further limit the subject matter of the previous claims, since the previous claims recite a "bovine" TNF-R1.

## Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

5. Claims 46-59 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. Claims 46-59 encompass nucleotides or polypeptides that are no less than the lengths recited in the claims, and these recited lengths are not present in the specification. On page 6, line 22, a fragment of 536 nucleotides is presented (nucleotides 378-923) and on page 5, line 21, a fragment of 543 nucleotides is recited. On page 6, lines 22-23, a fragment of 78 nucleotides is presented (nucleotides 924-1001). However, the fragment sizes recited in the claims are not present in the specification, and therefore is new matter.

#### Conclusion

- 6.1 Claims 29-40 and 59-62 are allowed.
- 6.2 Claims 41-44 are objected to.
- 6.3 Claims 45-58 are rejected.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Eileen B. O'Hara, whose telephone number is (571) 272-0878. The examiner can normally be reached on Monday through Friday from 10:00 AM to 6:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached at (571) 272-0871.

Official papers Before Final and After Final filed by RightFax should be directed to (703) 872-9306.

The customer service RightFax number is (703) 872-9305.

Official papers filed by fax should be directed to (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (571) 272-1600.

Eileen B. O'Hara, Ph.D.

Patent Examiner

LORRAINE SPECTOR PRIMARY EXAMINER